TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 1358-PCT-US-01

	CONCERNING A FILIN	U.S. APPLICATION NO. (If known, see 37 GFR 1.5)								
	ATIONAL APPLICATION NO. 1/02/41503	INTERNATIONAL FILING DATE 12/26/2002	PRIORITY DATE CLAIMED December 26, 2001							
TITLE OF INVENTION EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES										
APPLICA Henry D	NT(S) FOR DO/EO/US Daniell									
		Designated/Elected Office (DO/EO/US) the	following items and other information:							
1. 🛛	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.									
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3. 🗌	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.									
4. 🔲	The US has been elected (Article 31).									
5. 🛛	A copy of the International Application as filed (35 U.S.C. 371(c)(2))) a. ☐ is attached hereto (required only if not communicated by the International Bureau). b. ☐ has been communicated by the International Bureau. c. ☐ is not required, as the application was filed in the United States Receiving Office(RO/US)									
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4).									
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made.									
8. 🗌	An English language translation of	f the amendments to the claims under PC	T Article 19 (35 U.S.C. 371(c)(3)).							
9. 🛛	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).									
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).									
Items	s 11 to 20 below concern documer	nt(s) or information included:								
11. 🔲	An Information Disclosure Statem	ent under 37 CFR 1.97 and 1.98.								
12. 🔲	An assignment document for recording	g. A separate cover sheet in compliance with	37 CFR 3.28 and 3.31 is included.							
13. 🗌	A preliminary amendment.									
14. 🔲	An Application Data Sheet under	37 CFR 1.76.								
15. 🔲	A substitute specification.									
16. 🛛	A power of attorney and/or address	s letter.								
17. 🗌	A computer-readable form of the sec	quence listing in accordance with PCT Rule	: 13ter.2 and 35 U.S.C. 1.821 - 1.825.							
18. 🛚	A second copy of the published int	ternational application under 35 U.S.C. 13	54(d)(4). /							
19. 🗌	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
20. 🗌	Other items or information:									

page 1 of 2

U.S. APPLICATION D. Onder, 5300 1.35 INTERNATIONAL APPLICATION NO. 60/344,704					ATTORNEY'S DOCKET NUMBER 1358-PCT-US-01						
21. The following fee	CAL	CULATIONS	РТО	USE ONLY							
BASIC NATIONAI Neither international pr nor international search and International Search											
International preliminar USPTO but Internations											
International preliminar but international search											
International preliminar but all claims did not sa											
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)											
ENT	\$770)									
Surcharge of \$130.00 for from the earliest claime	\$										
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$							
Total Claims	44 - 20 =	24	x \$18.00	\$ 43	32						
Independent Claims	5 - 3 =	2	x \$86.00	17	72						
MULTIPLE DEPENDE	\$										
	\$1,3	74									
Applicant claims s are reduced by ½.	\$										
	\$1,3	74									
Processing fee of \$130. from the earliest claime	\$										
	\$ 1,3	374									
Fee for recording the en accompanied by an app	\$0										
	\$1,3	74									
					Amount to refund		\$350				
					charg	ed:	\$1,724				
a. 🛛 A check in the											
	Please charge my Deposit Account No. 13-3405 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.										
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposition Account No. <u>13-3405</u> . A duplicate copy of this sheet is enclosed.										
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
SEND ALL CORRESPON		114	10	Picos							
Schnader, Harrison, Seg. 1600 Market Street, Suit Philadelphia, PA, 19103- USA	4KD WEISER 1,763										
REGISTRATION NO.											

FORM PTO-1390 (REV 10-2003) page 2 of 2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

: not yet known

Examiner

: not yet known

Serial No.

: not yet known

Filed

: Herewith

Inventors

: Henry Daniell

Title

: EXPRESSION OF PROTECTIVE

ANTIGENS IN TRANSGENIC

CHLOROPLASTS AND THE PRODUCTION

OF IMPROVED VACCINES

Docket: 1358-PCT-US-01 Date: June 25, 2004

22469

PATENT TRADEMARK OFFICE

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Express Mail Label No.:

EL 315722759US

Date of Deposit:

June 25, 2004

For

Postcard

PTO-1390, in duplicate

Declaration for Utility or Design Patent Application

Check for \$1,724.00

PCT WO 03/057834 A2 Expression of Protective Antigens ... Improved Vaccines

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney or Registered Representative:

Schnader Harrison Segal & Lewis LLP

Customer No. 22469

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)